CorMedix Inc. (CRMD) stock
CRMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/30
$4.67−0.15 (-3.11%)
Close on Nov 17, 2026Market cap $364.00MP/E –Yield –
CorMedix r&d expenses
Research and development expenses are spending on new products and technology.
CorMedix's R&D Expenses for the twelve months ending Jun 30, 2026 was $27.59M, up 241.1% year over year. For fiscal 2025 it was $19.33M, up 390.4% from the year before. Over ten years it grew 11.9% a year on average. The highest annual figure on record is $24.49M in fiscal 2017.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.33M | +390.4% |
| FY2024 | Dec 31, 2024 | $3.94M | -70.0% |
| FY2023 | Dec 31, 2023 | $13.16M | +23.2% |
| FY2022 | Dec 31, 2022 | $10.68M | -18.7% |
| FY2021 | Dec 31, 2021 | $13.13M | -1.8% |
| FY2020 | Dec 31, 2020 | $13.38M | +21.0% |
| FY2019 | Dec 31, 2019 | $11.05M | -41.3% |
| FY2018 | Dec 31, 2018 | $18.82M | -23.1% |
| FY2017 | Dec 31, 2017 | $24.49M | +55.6% |
| FY2016 | Dec 31, 2016 | $15.74M | +150.5% |
| FY2015 | Dec 31, 2015 | $6.28M | +376.4% |
| FY2014 | Dec 31, 2014 | $1.32M | +7.5% |
| FY2013 | Dec 31, 2013 | $1.23M | +7.4% |
| FY2012 | Dec 31, 2012 | $1.14M | -71.8% |
| FY2011 | Dec 31, 2011 | $4.06M | -26.1% |
| FY2010 | Dec 31, 2010 | $5.49M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $6.68M | +173.7% |
| Q1 FY2026 | Mar 31, 2026 | $7.21M | +125.9% |
| Q4 FY2025 | Dec 31, 2025 | $8.60M | +398.1% |
| Q3 FY2025 | Sep 30, 2025 | $5.10M | +601.1% |
| Q2 FY2025 | Jun 30, 2025 | $2.44M | +275.1% |
| Q1 FY2025 | Mar 31, 2025 | $3.19M | +281.3% |
| Q4 FY2024 | Dec 31, 2024 | $1.73M | -24.6% |
| Q3 FY2024 | Sep 30, 2024 | $727.12K | -72.7% |
| Q2 FY2024 | Jun 30, 2024 | $650.99K | -86.4% |
| Q1 FY2024 | Mar 31, 2024 | $837.45K | -75.4% |
| Q4 FY2023 | Dec 31, 2023 | $2.29M | -19.5% |
| Q3 FY2023 | Sep 30, 2023 | $2.66M | +13.9% |
| Q2 FY2023 | Jun 30, 2023 | $4.79M | +49.4% |
| Q1 FY2023 | Mar 31, 2023 | $3.41M | +49.0% |
| Q4 FY2022 | Dec 31, 2022 | $2.84M | -12.1% |
| Q3 FY2022 | Sep 30, 2022 | $2.34M | -50.7% |
| Q2 FY2022 | Jun 30, 2022 | $3.21M | +27.3% |
| Q1 FY2022 | Mar 31, 2022 | $2.29M | -13.2% |
| Q4 FY2021 | Dec 31, 2021 | $3.24M | +41.0% |
| Q3 FY2021 | Sep 30, 2021 | $4.74M | +62.1% |
| Q2 FY2021 | Jun 30, 2021 | $2.52M | -55.7% |
| Q1 FY2021 | Mar 31, 2021 | $2.64M | +6.6% |
| Q4 FY2020 | Dec 31, 2020 | $2.29M | -14.3% |
| Q3 FY2020 | Sep 30, 2020 | $2.93M | +16.0% |
| Q2 FY2020 | Jun 30, 2020 | $5.69M | +90.8% |
| Q1 FY2020 | Mar 31, 2020 | $2.47M | -14.0% |
| Q4 FY2019 | Dec 31, 2019 | $2.68M | -67.7% |
| Q3 FY2019 | Sep 30, 2019 | $2.52M | -61.8% |
| Q2 FY2019 | Jun 30, 2019 | $2.98M | -64.0% |
| Q1 FY2019 | Mar 31, 2019 | $2.87M | -66.0% |
| Q3 FY2018 | Sep 30, 2018 | $8.29M | +37.8% |
| Q2 FY2018 | Jun 30, 2018 | $6.60M | +29.7% |
| Q1 FY2018 | Mar 31, 2018 | $8.28M | +68.2% |
| Q4 FY2017 | Dec 31, 2017 | $8.46M | +209671.1% |
| Q3 FY2017 | Sep 30, 2017 | $6.01M | -12.1% |
| Q2 FY2017 | Jun 30, 2017 | $5.09M | – |
| Q1 FY2017 | Mar 31, 2017 | $4.92M | – |
| Q4 FY2016 | Dec 31, 2016 | $4.03K | – |
| Q3 FY2016 | Sep 30, 2016 | $6.84M | – |
See a number that looks wrong?